From 31 centers, 166 patients were entered. Of this intent-to-treat group, 48% responded. With a median follow-up duration of 11.8 months, the projected median time to progression for responders is 13 ...
The "Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2014-2020" report has been added to ResearchAndMarkets.com’s offering. The Global Cancer Monoclonal Antibody Partnering Terms and ...
In 1975, Georges Köhler and César Milstein, biochemists from the Medical Research Council Laboratory of Molecular Biology, published a paper in Nature about a hybridoma technology that enabled the ...
Jan Vilcek, M.D., Ph.D., is a professor of microbiology at New York University Langone Medicine Center. Research in his laboratory led to the development of cA2, the first chimeric monoclonal antibody ...
This review focuses on patient care tips and practices for the care of patients with B-NHL or MM receiving bispecific antibody therapy.
Antibodies are a critical feature of the human adaptive immune response. New immunotherapies require the production of selective and non-autoimmunogenic antibodies. These engineered antibodies can ...
Integral Molecular Uses Shotgun Mutagenesis to Germline-Humanize Monoclonal Antibodies Seventy percent of FDA-approved monoclonal antibodies (mAbs) and approximately 66% of mAbs currently in clinical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results